Literature DB >> 18036633

Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice.

William E Grizzle1, Xin Xu, Shuangqin Zhang, Cecil R Stockard, Cunren Liu, Shaohua Yu, Jianhua Wang, John D Mountz, Huang-Ge Zhang.   

Abstract

In this study, our data show that in young BXD12 mice, the implanted TS/A tumor regressed in 4 weeks after implantation, and this regression was associated with extensive T cell infiltration. In contrast, in old BXD12 mice, it was observed that there was rapid tumor growth by 7 weeks. T cell cytotoxicity against TS/A tumor cells exhibited a significant age-related decline, which was correlated with a decline in CD3(+) T cell infiltration of the tumor. Furthermore, the decline of T cell tumor cytotoxicity in aged BXD12 mice was also correlated with the accumulation of CD11b(+)Gr1(+) myeloid-derived suppressor cells in the spleen. Adoptive transfer of these accumulated CD11b(+)Gr1(+)cells from aged mice to 2-month-old BXD12 mice led to the delay of the rejection of implanted tumor cells. The depletion of CD11b(+)Gr1(+)cells from aged BXD12 mice led to the slower growth of tumor. Induction of arginase 1 in myeloid cells isolated from aged mice plays a partial role in immune suppression of T cell cytotoxicity. Thus, the accumulation of immunosuppresssing myeloid cells appears to contribute to the increase of tumor susceptibility as the age of mice increases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18036633     DOI: 10.1016/j.mad.2007.10.003

Source DB:  PubMed          Journal:  Mech Ageing Dev        ISSN: 0047-6374            Impact factor:   5.432


  45 in total

Review 1.  Cognitive and behavioral consequences of impaired immunoregulation in aging.

Authors:  Angela W Corona; Ashley M Fenn; Jonathan P Godbout
Journal:  J Neuroimmune Pharmacol       Date:  2011-09-20       Impact factor: 4.147

Review 2.  Gut dysbiosis: a potential link between increased cancer risk in ageing and inflammaging.

Authors:  Arya Biragyn; Luigi Ferrucci
Journal:  Lancet Oncol       Date:  2018-06-01       Impact factor: 41.316

Review 3.  Is cancer vaccination feasible at older age?

Authors:  Claudia Gravekamp; Arthee Jahangir
Journal:  Exp Gerontol       Date:  2014-02-06       Impact factor: 4.032

4.  Tolerance and immune suppression in the tumor microenvironment.

Authors:  Suzanne Ostrand-Rosenberg
Journal:  Cell Immunol       Date:  2015-09-30       Impact factor: 4.868

5.  Immunity, cancer and aging: lessons from mouse models.

Authors:  Cheryl E Myers; Noweeda N Mirza; Joseph Lustgarten
Journal:  Aging Dis       Date:  2011-12-02       Impact factor: 6.745

Review 6.  The impact of aging on cancer vaccination.

Authors:  Claudia Gravekamp
Journal:  Curr Opin Immunol       Date:  2011-07-18       Impact factor: 7.486

Review 7.  Considerations for successful cancer immunotherapy in aged hosts.

Authors:  V Hurez; Á S Padrón; R S Svatek; T J Curiel
Journal:  Clin Exp Immunol       Date:  2016-11-07       Impact factor: 4.330

Review 8.  Optimization of immunotherapy in elderly cancer patients.

Authors:  Kei Tomihara; Tyler J Curiel; Bin Zhang
Journal:  Crit Rev Oncog       Date:  2013

Review 9.  Aging and cancer vaccines.

Authors:  Claudia Gravekamp; Dinesh Chandra
Journal:  Crit Rev Oncog       Date:  2013

Review 10.  Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.

Authors:  Katherine H Parker; Daniel W Beury; Suzanne Ostrand-Rosenberg
Journal:  Adv Cancer Res       Date:  2015-05-12       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.